Inflammatory bowel disease can remain quiet for months or even years before suddenly flaring again. New research suggests that even when Crohn’s disease or ulcerative colitis appear well controlled, the intestinal lining may remain biologically vulnerable in ways that conventional tests fail to detect.
Inflammatory bowel disease (IBD) affects an estimated 7 million people worldwide, with cases increasing in many countries. Current treatments primarily aim to suppress inflammation and achieve clinical remission, when symptoms improve and routine indicators of disease activity return to normal.
What the new study reveals
Researchers from the Walter and Eliza Hall Institute and the Royal Melbourne Hospital analyzed more than 900 intestinal biopsies collected from 80 people with and without IBD. Most participants with IBD had inactive or only mildly active disease when their samples were taken.
The team focused on the intestinal epithelium, a single-cell-thick layer that lines the gut and continuously renews itself. Besides absorbing nutrients, this protective barrier helps defend the body against harmful microbes and toxins, making its integrity essential for long-term intestinal health.
Under normal conditions, epithelial cells are removed through apoptosis, a carefully regulated form of programmed cell death. Stem cells located in intestinal crypts replace these cells, maintaining the protective barrier. However, the researchers found that inflammation appears to alter epithelial cells, making them more vulnerable to damaging signals that trigger cell death.
Cell death pathways under scrutiny
Intestinal biopsies from people with IBD contained elevated molecular markers associated with necroptosis, a disruptive form of cell death that can cause cells to rupture and release inflammatory substances into surrounding tissue. These signals were detected even in areas showing only mild inflammation under microscopic examination.
To investigate these processes further, researchers developed three-dimensional miniature intestines, known as organoids, using tissue obtained from patients. These laboratory-grown structures allowed scientists to expose intestinal cells to inflammatory molecules and examine their responses outside the body.
Unexpectedly, when the organoids were exposed to inflammatory signals, most cells died through apoptosis rather than necroptosis. Blocking necroptosis did not prevent cell loss under these experimental conditions, suggesting that several overlapping cell-death mechanisms may contribute to damage in the intestinal lining.
Genetic experiments also revealed that removing certain genes could protect particular types of epithelial cells. However, developing safe treatments based on these findings will require further investigation, since interfering with normal cell-death processes could increase the risk of infections or even cancer.
Could this predict future flares?
The researchers also investigated whether early changes in intestinal tissue might be associated with subsequent disease relapses. Of the 52 patients with IBD whose biopsies were examined, 30 had follow-up information covering approximately two to three years, while 22 were lost to follow-up.
Among the patients who were monitored, 16 experienced a flare requiring stronger or different treatment, while 14 remained stable. Those who subsequently relapsed had higher baseline levels of a key cell-death signaling marker compared with individuals without IBD.
These patients also showed greater microscopic inflammation, even when their symptoms were relatively mild. The findings suggest that molecular changes within intestinal tissue, beyond what standard endoscopy and blood tests reveal, might eventually help identify people at increased risk of future flares.
However, the study was too small to establish whether these markers can reliably predict which patients will experience a relapse. Larger prospective studies will be necessary before tests based on epithelial cell-death signatures can be considered clinically useful.
Toward deeper healing in IBD
The findings support a growing understanding that clinical remission does not necessarily mean complete biological healing in inflammatory bowel disease. Even after abdominal pain, diarrhea and bleeding improve, the intestinal barrier may remain weakened, potentially increasing vulnerability to renewed inflammation.
Experts suggest that future treatments may need to combine immune suppression with approaches designed to protect and repair the intestinal epithelium. Potential strategies include medications that strengthen barrier function, encourage healthy stem-cell renewal or carefully regulate cell-death pathways without compromising essential protective mechanisms.
Such treatments would require a careful balance between potential benefits and risks. Cell death plays a vital role in removing infected, damaged and precancerous cells. Suppressing this process excessively could have serious long-term consequences, making rigorous clinical trials essential.
The research, published in Science in 2024, highlights a developing approach to IBD treatment that some specialists describe as molecular healing. Rather than focusing exclusively on reducing inflammation, the goal would be to restore normal biological processes within the intestinal lining and potentially reduce recurring disease flares.
For patients, these findings are unlikely to change treatment immediately. However, they offer a possible explanation for why inflammatory bowel disease can return despite apparent remission and point toward a future in which more precise assessments of intestinal tissue could support personalized care.
